Weight-loss drug powers Lilly results, 2024 forecast raised by $3 billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Eli Lilly (LLY) PT Raised to $1,150 at BofA Securities
August 9, 2024 5:56 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Eli Lilly (NYSE: LLY) to $1,150.00 (from $1,000.00) while maintaining a Buy rating.
The analyst comments "LLY shares traded with strength today (+9.5%; DRG index: +4%) following the continued outperformance from Lillys incretin portfolio, including Mounjaro (Type 2 diabetes) and Zepbound (obesity). Importantly, given managements... More
